News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novavax, Inc. (NVAX) Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate


7/8/2013 9:59:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., July 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 clinical trial of its monovalent virus-like particle (VLP) vaccine candidate for the prevention of disease due to A/Anhui/1/13-like A(H7N9) avian influenza viruses (A(H7N9) vaccine).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES